Innovent Biologics, Inc.

• ESMO26: Takeda, Innovent's gastric cancer ADC cuts risk of death by 43%
  FirstWord Pharma · 23 Oct 2026
• Innovent Biologics, Inc. Estimates – SWB:6IB
  TradingView · 23 Oct 2026
• ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
  Fierce Biotech · 23 Oct 2026
• Innovent's Sycume meets phase 3 endpoint for inactive TED
  Glance by Eyes On Eyecare · 20 Oct 2026
• Is Innovent Biologics (SEHK:1801) A Bargain After SYCUME Phase 3 Results?
  Simply Wall Street · 17 Oct 2026
• Innovent's Sycume meets primary endpoint in Phase III trial in inactive thyroid eye disease
  The Pharma Letter · 12 Oct 2026
• Innovent's Sycume hits Phase III endpoint in Chinese thyroid eye disease trial
  AllSci · 09 Oct 2026
• Innovent's Sycume Meets Phase 3 Goal in Inactive Thyroid Eye Disease
  BioPharm International · 09 Oct 2026
• Innovent flexes Phase III win for anti-IGF-1R antibody in inactive thyroid eye disease
  FirstWord Pharma · 09 Oct 2026
• Innovent expands MarsLight-11 study. CLSA keeps HKD 146.10 target for Innovent stock
  AD HOC NEWS · 07 Oct 2026
• Innovent Sets 2030 Revenue Forecast as GLP-1 and Oncology Treatments Are Main Drivers
  Morningstar · 29 Sep 2026
• Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
  Clinical Trials Arena · 28 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →